On June 30, the Company held an all-staff meeting to comprehensively review the achievements of the first half of the year and sound the call to action for the second half. Yu-chong Tai, a member of the U.S. National Academy of Engineering and the American Institute for Medical and Biological Engineering (co-founder of IntelliMicro and professor at the California Institute of Technology), attended the meeting. Xiang Zhenfei, the Company’s chairman and president, and Tian Ping, vice president, delivered important speeches.
Tian Ping, the Company’s Vice President, stated that over the past few years, all staff of IntelliMicro have stood together through thick and thin, overcoming challenges, and that the Company is now standing at the forefront of the brain-computer interface(BCI) industry. He pointed out that IntelliMicro possesses three unparalleled strengths: a team of scientists led by top-tier academicians; the IMIE intelligent retina and several other industry-leading advanced products; and a promising future with a clear, diversified strategic layout and a well-defined path to financing and listing. He emphasized the need to seize this window of opportunity, steadily reduce costs and improve efficiency, and accelerate progress toward the IPO stage.
Academician Yuc-hong Tai subsequently delivered an important speech. He stated that IntelliMicro is entering a critical moment for full-scale takeoff. Driven by both government policy support for the BCI industry and breakthroughs in cutting-edge technology, the first-launched IMIE project is accelerating its clinical trials. He emphasized that IMIE is not merely a product but a technological platform that can generate a series of innovative achievements. He encouraged all employees to stay committed to the path, accelerate clinical trials, and safeguard human health through advanced technology.
Xiang Zhenfei, Chairman and President of the Company, delivered a mobilization speech centered on the theme of “overcoming challenges.” He pointed out that IntelliMicro is engaged in the noble cause of benefiting patients, and that the nation has high hopes for breakthroughs in BCI technology; the Company will continue to advance the clinical trials and product registration for the IMIE product. He reflected on the team’s journey of overcoming challenges along the way and urged all employees to broaden their perspectives, pull together, and always believe in “the power of belief.” Looking ahead, the Company will seize the opportunity presented by the establishment of the International Science and Technology Innovation Center for Human-Computer Interface Applications to fully overcome key hurdles in clinical translation and market launch. All IntelliMicro employees must continue to align closely with the Company’s strategy, tackle challenges with the determination of climbers, and use more groundbreaking achievements to fulfill the earnest hopes of countless people with disabilities.